Preclinical Research in Industry

Thursday, 27 June 2024, 12:00 – 12:45 

David Maussang-Detaille | Executive Director Preclinical Research and Portfolio Management, Merus

David Maussang-Detaille obtained his PhD at VU Amsterdam (NL) where he investigated the link between the viral G protein-coupled receptor US28 and the formation of tumors. During that time, he expanded his expertise in mouse in vivo models at Mount Sinai School of Medicine in New York (USA). In his postdoctoral fellowship, David gained interest in the use of antibody-derived therapeutics as potential treatment options and participated to the academic-industry collaboration between VU Amsterdam and Ablynx (now part of Sanofi). Afterwards, he started his industry career as scientist at to-BBB Technologies in Leiden, prior to joining Merus in 2014. Since then, David has experienced various roles within Merus Research department, from senior scientist to project manager and ultimately Executive Director Preclinical Research and Portfolio Management. In his current role, David is responsible for Merus’ largest external Research collaboration, the definition and execution of Merus Research portfolio, as well as for several other operational projects.

Merus

Merus NV (Merus) is a clinical-stage biotechnology company developing multispecific antibodies referred to as Multiclonics® to address unmet needs of patients with various types of cancer. The therapeutic candidates are designed to engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways. The clinical pipeline is composed of several bispecific antibody candidates, with several other candidates in pre-clinical development. Merus has been a publicly traded company on the Nasdaq since 2016. Merus’ headquarters are located in Utrecht, the Netherlands, with a subsidiary, Merus US Inc., located in Cambridge (MA) in the USA and collaborators, licensees and clinical trial sites located around the world.

Preclinical Research in Industry

David will present Merus’ story and share some aspects of industrial Research activities. Talking about his career path and possibilities within Merus, David aims to share an interesting perspective on career evolution to the participants of the BioBusiness Summer School 2024.